Induction Chemotherapy in Esophageal Cancer: Is the “Head Start” Worth the Wait?
The “In a Nutshell” Intro While definitive chemoradiotherapy (dCRT) is the gold standard for non-surgical esophageal cancer, systemic relapse remains a formidable foe for over 50% of patients. This post explores whether “bioselection” via induction chemotherapy (IC) can actually move the needle on survival or if it’s just delaying the inevitable.